Cover Image
市場調查報告書

全球體外診斷用醫藥品 (IVD) 的聯盟契約趨勢:2010-2016年

Global In Vitro Diagnostics Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 355308
出版日期 內容資訊 英文 660 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球體外診斷用醫藥品 (IVD) 的聯盟契約趨勢:2010-2016年 Global In Vitro Diagnostics Partnering 2010-2016: Deal Trends, Players, Financials and Forecasts
出版日期: 2016年11月18日 內容資訊: 英文 660 Pages
簡介

本報告提供體外診斷用醫藥品 (IVD) 相關的各種聯盟契約趨勢的相關調查,近幾年所簽訂的各種契約趨勢,大規模契約及大型經營者的契約概要,契約區分、開發階段、治療領域、各技術類型的一覽等彙整資料。

第1章 簡介

第2章 體外診斷用醫藥品 (IVD) 相關合約趨勢

  • 簡介
  • 過去數年的聯盟趨勢
  • 聯盟契約最活躍的經營者
  • 聯盟契約:各契約種類
  • 聯盟契約:各治療領域
  • 聯盟契約的條件
    • 交易總額
    • 契約退職金
    • 里程碑付款
    • 權利金比率

第3章 主要契約

  • 簡介
  • 主要契約:各契約金額

第4章 聯盟契約最活躍的經營者

  • 簡介
  • 聯盟契約最活躍的經營者
  • 聯盟契約最活躍的經營者簡介

第5章 聯盟契約目錄

  • 簡介
  • 聯盟契約目錄

第6章 體外診斷用醫藥品 (IVD) 相關合約:各技術區分

第7章 聯盟契約資源中心

  • 線上基於的聯盟
  • 聯盟活動
  • 聯盟契約相關資料

附錄1:聯盟契約 - 各企業 (A-Z)

附錄2:聯盟契約 - 各開發階段

  • 藥物研發
  • 前臨床
  • 第一階段
  • 第二階段
  • 第三階段
  • 申請階段
  • 已上市
  • 調劑階段

附錄3:聯盟契約 - 各類型

  • 資產購買
  • 轉讓
  • 生物醫藥品對外授權
  • 共同開發
  • 共同R&D
  • 共同販賣
  • 共同促銷
  • CRADA
  • 交叉授權
  • 開發
  • 流通銷售
  • 股票購買
  • 評估
  • 津貼
  • 合資企業
  • 授權
  • 訴訟
  • 製造
  • 行銷
  • 物質移動
  • 選擇
  • 推銷
  • 研究
  • 協定
  • 衍生公司
  • 輔助許可證
  • 供給
  • 技術轉移
  • 契約解除
  • 保證

附錄4:聯盟契約 - 各治療領域

附錄5 -聯盟區分定義

關於Wildwood Ventures

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2120

The ‘Global In Vitro Diagnostics Partnering 2010-2016 ’ report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest In Vitro Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.

The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 400 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of In Vitro Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in In Vitro Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading In Vitro Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in In Vitro Diagnostics dealmaking with a brief summary followed by a comprehensive listing of In Vitro Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific In Vitro Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in In Vitro Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.

Key benefits

‘Global In Vitro Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts ’ provides the reader with the following key benefits:

  • In-depth understanding of In Vitro Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of In Vitro Diagnostics agreements with numerous real life case studies
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2010
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global In Vitro Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts ’ is intended to provide the reader with an in-depth understanding and access to In Vitro Diagnostics trends and structure of deals entered into by leading companies worldwide.

‘In Vitro Diagnostics Partnering Terms and Agreements ’ includes:

  • Trends in In Vitro Diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of In Vitro Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life In Vitro Diagnostics deals
  • Access to In Vitro Diagnostics contract documents
  • Leading In Vitro Diagnostics deals by value since 2010
  • Most active In Vitro Diagnostics dealmakers since 2010

In ‘Global In Vitro Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts ’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global In Vitro Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts ’ report provides comprehensive access to available deals and contract documents for over 400 In Vitro Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in In Vitro Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. In Vitro Diagnostics partnering over the years
  • 2.3. Most active In Vitro Diagnostics dealmakers
  • 2.4. In Vitro Diagnostics partnering by deal type
  • 2.5. In Vitro Diagnostics partnering by therapy area
  • 2.6. Deal terms for In Vitro Diagnostics partnering
    • 2.6.1. In Vitro Diagnostics partnering headline values
    • 2.6.2. In Vitro Diagnostics deal upfront payments7
    • 2.6.3. In Vitro Diagnostics deal milestone payments
    • 2.6.4. In Vitro Diagnostics royalty rates

Chapter 3 - Leading In Vitro Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top In Vitro Diagnostics deals by value

Chapter 4 - Most active In Vitro Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active In Vitro Diagnostics dealmakers
  • 4.3. Most active In Vitro Diagnostics partnering company profiles

Chapter 5 - In Vitro Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. In Vitro Diagnostics contracts dealmaking directory

Chapter 6 - In Vitro Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - In Vitro Diagnostics deals by company A-Z

Appendix 2 - In Vitro Diagnostics deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - In Vitro Diagnostics deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - In Vitro Diagnostics deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: In Vitro Diagnostics partnering since 2010
  • Figure 2: Active In Vitro Diagnostics dealmaking activity- 2010 to 2016
  • Figure 3: In Vitro Diagnostics partnering by deal type since 2010
  • Figure 4: In Vitro Diagnostics partnering by disease type since 2010
  • Figure 5: In Vitro Diagnostics deals with a headline value
  • Figure 6: In Vitro Diagnostics deals with an upfront value
  • Figure 7: In Vitro Diagnostics deals with a milestone value
  • Figure 8: In Vitro Diagnostics deals with a royalty rate value
  • Figure 9: Top In Vitro Diagnostics deals by value since 2010
  • Figure 10: Most active In Vitro Diagnostics dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top